Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

EntreMed reports net loss of $2.6 million for first quarter 2011

EntreMed, Inc., a clinical-stage pharmaceutical company, today announced financial results for the three months ended March 31, 2011.

16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

Researchers untangle two distinct ways in which tumor-suppressor protein works

Researchers at the Stanford University School of Medicine have untangled two distinct ways in which a common, naturally occurring "tumor-suppressor" protein works.

13 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor. The funds will be used to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis, also known as bladder pain syndrome. The first trial is projected to start in the second half of this year.

12 May 2011

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

Leukemia is the most common childhood cancer; it also occurs in adults. Now researchers working with zebrafish at Huntsman Cancer Institute (HCI) at the University of Utah have identified previously undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia (T-ALL), according to an article published online May 9, 2011, in the cancer research journal Oncogene.

11 May 2011

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis.

11 May 2011

Micromet first quarter total revenues decrease to $5.5 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the first quarter ended March 31, 2011.

10 May 2011

EpiCept first quarter net loss decreases to $2.5 million

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2011, and provided an update with respect to the Company's key business initiatives.

10 May 2011

MHA's annual awards recognize outstanding health care leaders, innovative programs

Innovative programs and outstanding leaders in health care were honored Friday, May 6 at the Minnesota Hospital Association's 27th annual awards ceremony at the Metropolitan Ballroom in Minneapolis.

10 May 2011

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

The field of adolescent and young adult oncology reflects the growing recognition that this group of patients and survivors are not just "old" pediatric patients or "young" adult patients.

9 May 2011

Karmanos Cancer Institute raises funds for patient care and research

More than 450 guests attended the Barbara Ann Karmanos Cancer Institute's 29th Annual Dinner gala on Saturday, April 30, at the beautiful General Motors Heritage Center, in Sterling Heights. Dan Akerson, chairman and chief executive officer for General Motors Company, and his wife Karin, chaired the event.

9 May 2011

Brain cancer research needs $50 billion to find cure

According to one of Australia's leading neurosurgeons a massive increase in funding is needed to find a cure for brain cancer. Brain cancer kills one Australian every eight hours. About 1,400 cases of malignant brain cancer are diagnosed in Australia every year and about 1,100 people die from the disease.

8 May 2011

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

A new effort led by a University of California, Irvine Medical Center oncologist seeks to improve cancer survival for adolescents and young adults. Dr. Leonard S. Sender has long advocated changing the approach oncologists take when treating patients and survivors aged 15 to 39.

7 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

The most comprehensive analysis yet of the epigenetic modifications present in breast cancer has revealed potentially important new ways to detect and treat the disease, Belgian researchers have reported.

5 May 2011

Leukemia News and Research

Further Reading

EntreMed reports net loss of $2.6 million for first quarter 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Researchers untangle two distinct ways in which tumor-suppressor protein works

New study sheds light on origins of myeloid leukemia

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Inovio first quarter total revenue increases to $3.1 million for 2011

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

Micromet first quarter total revenues decrease to $5.5 million

EpiCept first quarter net loss decreases to $2.5 million

MHA's annual awards recognize outstanding health care leaders, innovative programs

Mary Ann Liebert publishes new journal on cancer care for adolescent and young adult patients

Karmanos Cancer Institute raises funds for patient care and research

Brain cancer research needs $50 billion to find cure

University of California, Irvine Medical Center introduce Journal of Adolescent and Young Adult Oncology

CytRx reports $6.3 million net loss for first quarter 2011

Genome epigenetic analysis reveals new ways to detect and treat breast cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News